Avid Bioservices Inc (CDMO)

[2ndstr2thert]

Ftm Bavituximab may need BGP21 to bind to PS but pgn632 is BGP21 independent.

re


Genentech studying Imaging using PGN635(Fhu-Bavi): 10-12-12 article...

Genentech studying Imaging using PGN635(Fhu-Bavi) for the potential “detection of tumor response to therapy”. 9 Genentech co-authors of new paper pub. 10-12-2012 in Nuclear Medicine & Biology, which acknowledges Dr. Philip Thorpe & Peregrine, and states in the article, “the presented PS-targeting antibody (89Zr-PGN635) has a potential to become a broadly applicable imaging agent indep. on cancer type since PS is a generic component of the plasma membrane.”… [Thanks, FTM – great find]…

Note: 89Zr-PGN635 is a different imaging agent than used in the ongoing Imaging trial, which uses 124I-PGN650 ( http://clinicaltrials.gov/ct2/show/NCT01632696 ).
…Recall:
• PGN635 is Fully-Human Bavituximab=1N11=AT004 (B2GPI-depen.); Genentech studying 89Zr-PGN635 as a Tumor Imaging Agent, “indep. of cancer type”
• PGN632 is the Duke-PPHM-HIV candidate=11.31=AT005 (B2GPI-indep.); also being studied by PPHM+LSU vs. Ocular Herpes (Acute HSV-1 Keratitis), see http://tinyurl.com/cax9a4p
• PGN650 is a human F(ab’)2 fragment that targets PS expression (1st ref’d in AACR’12 #2452) – see http://tinyurl.com/76nqqkm . 124I-PGN650 is Peregrine’s PS-Imaging candidate, whose IND clinical filing was announced 4-3-12, and whose n=12 trial started 6-2012.
- - - - - - - - -
Note: PGN632 (Duke/HIV preclin’s) binds to PS indep. of B2-glycoprotein I (B2GPI), unlike Bavi & FH-Bavituximab(PGN635) which depend on B2GPI as a binding intermediary.

=